Literature DB >> 3361077

Criteria for the cure of acromegaly: comparison between basal growth hormone and somatomedin C plasma concentrations in active and non-active acromegalic patients.

D Giannella-Neto1, B L Wajchenberg, B B Mendonça, S F Almeida, M Macchione, E M Spencer.   

Abstract

Fasting plasma growth hormone (GH) and somatomedin C (SmC) levels were compared as criteria for the cure of acromegaly in 7 untreated and 16 treated acromegalic patients studied 1 to 16 yr after pituitary surgery and/or radiotherapy. The patients without active disease presented a significant correlation between GH and SmC. Only when basal GH was lower than 2.5 ng/ml were SmC values within the normal range. The subjects with active acromegaly (both treated and untreated) presenting GH higher than 5 ng/ml did not show any correlation between GH and SmC levels.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3361077     DOI: 10.1007/BF03350100

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  14 in total

1.  Critical study of the growth hormone response to dynamic tests and the insulin growth factor assay in acromegaly after microsurgery.

Authors:  G Schaison; B Couzinet; N Moatti; B Pertuiset
Journal:  Clin Endocrinol (Oxf)       Date:  1983-06       Impact factor: 3.478

2.  Changes in circulating somatomedin-C levels in bromocriptine-treated acromegaly.

Authors:  J A Wass; D R Clemmons; L E Underwood; I Barrow; G M Besser; J J Van Wyk
Journal:  Clin Endocrinol (Oxf)       Date:  1982-10       Impact factor: 3.478

3.  The importance of insulin-like growth factor (somatomedin) measurements in the diagnosis and surveillance of acromegaly.

Authors:  M Rieu; F Girard; H Bricaire; M Binoux
Journal:  J Clin Endocrinol Metab       Date:  1982-07       Impact factor: 5.958

4.  A naturally occurring structural variant of human growth hormone.

Authors:  U J Lewis; J T Dunn; L F Bonewald; B K Seavey; W P Vanderlaan
Journal:  J Biol Chem       Date:  1978-04-25       Impact factor: 5.157

5.  Dwarfism associated with normal serum growth hormone and increased bioassayable, receptorassayable, and immunoassayable somatomedin.

Authors:  R Lanes; L P Plotnick; E M Spencer; W H Daughaday; A A Kowarski
Journal:  J Clin Endocrinol Metab       Date:  1980-03       Impact factor: 5.958

6.  Radioimmunoassay for non-suppressible insulin-like activity.

Authors:  K Reber; R Liske
Journal:  Horm Res       Date:  1976

7.  Somatomedin C in treated acromegaly: poor correlation with growth hormone and clinical response.

Authors:  L D Stonesifer; R M Jordan; P O Kohler
Journal:  J Clin Endocrinol Metab       Date:  1981-11       Impact factor: 5.958

8.  Hyperprolactinemia is associated with increased immunoreactive somatomedin C in hypopituitarism.

Authors:  D R Clemmons; L E Underwood; E C Ridgway; B Kliman; J J Van Wyk
Journal:  J Clin Endocrinol Metab       Date:  1981-04       Impact factor: 5.958

9.  The treatment of acromegaly by transsphenoidal surgery.

Authors:  H S Tucker; S R Grubb; J P Wigand; C O Watlington; W G Blackard; D P Becker
Journal:  Arch Intern Med       Date:  1980-06

10.  Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation.

Authors:  G Oppizzi; M M Petroncini; D Dallabonzana; R Cozzi; G Verde; P G Chiodini; A Liuzzi
Journal:  J Clin Endocrinol Metab       Date:  1986-12       Impact factor: 5.958

View more
  5 in total

1.  Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients.

Authors:  C Invitti; L Fatti; M G Camboni; L Porcu; L Danesi; G Delitala; F Cavagnini
Journal:  J Endocrinol Invest       Date:  1996-09       Impact factor: 4.256

2.  Hormonal and radiological effects of megavoltage radiotherapy in patients with growth hormone-secreting pituitary adenoma.

Authors:  E Ciccarelli; M R Valetto; E Vasario; T Avataneo; S Grottoli; F Camanni
Journal:  J Endocrinol Invest       Date:  1993-09       Impact factor: 4.256

Review 3.  Current status and future opportunities for controlling acromegaly.

Authors:  Shlomo Melmed; Mary Lee Vance; Ariel L Barkan; Bengt-Ake Bengtsson; David Kleinberg; Anne Klibanski; Peter J Trainer
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

Review 4.  Acromegaly. Recognition and treatment.

Authors:  C A Jaffe; A L Barkan
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

5.  Postoperative Changes in Metabolic Parameters of Patients with Surgically Controlled Acromegaly: Assessment of New Stringent Cure Criteria.

Authors:  Masanori Yonenaga; Shingo Fujio; Mika Habu; Hiroshi Arimura; Takaaki Hiwatari; Shunichi Tanaka; Yasuyuki Kinoshita; Hiroshi Hosoyama; Hirofumi Hirano; Kazunori Arita
Journal:  Neurol Med Chir (Tokyo)       Date:  2018-02-23       Impact factor: 1.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.